Key facts
- Transposon’s last known valuation is $95.2M (Dec 2020).
- It has raised $54.9M; the latest was Later Stage VC in Jul 2025.
- Notable investors include Canaan Partners, Osage University Partners, SV Health Investors, Domain Associates, Alzheimers Drug Discovery Foundation — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Transposon
- ·The full record, as it builds
Funding rounds
No funding rounds for Transposon are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Transposon
Operator of a clinical-stage startup company intended to develop novel drugs for neurodegenerative diseases and diseases of ageing. The company develops nucleoside inhibitors of reverse transcriptase and other mediators of pathology for the treatment of neurodegenerative disease, enabling patients to get treatment for debilitating and life-threatening diseases.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2019
- Employees
- 12
- Website
- transposonrx.com/
- Ownership
- Privately Held (backing)
Transposon doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Transposon shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Transposon in its N-PORT filings yet. We sweep new filings monthly.